RO5444101 (Figure 7) was first reported by Hoffman La Roche, Basel, Switzerland as a CatS selective inhibitor in the management of atherosclerosis in Apolipoprotein E deficient mice suffering from chronic renal disease [45]. Here, PIMREG is linked to atherosclerosis.